Qualigen Therapeutics, Inc.
QLGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $5 | $5 | $6 |
| % Growth | -100% | 4.4% | -11.9% | – |
| Cost of Goods Sold | $0 | $5 | $4 | $4 |
| Gross Profit | $0 | -$0 | $1 | $1 |
| % Margin | – | -0.1% | 13.7% | 23.4% |
| R&D Expenses | $1 | $5 | $7 | $12 |
| G&A Expenses | $4 | $6 | $11 | $12 |
| SG&A Expenses | $4 | $6 | $12 | $12 |
| Sales & Mktg Exp. | $0 | -$0 | $1 | $1 |
| Other Operating Expenses | $0 | -$5 | $0 | $0 |
| Operating Expenses | $6 | $6 | $19 | $24 |
| Operating Income | -$6 | -$11 | -$18 | -$23 |
| % Margin | – | -217.2% | -360% | -400.9% |
| Other Income/Exp. Net | -$0 | -$1 | $1 | $5 |
| Pre-Tax Income | -$6 | -$12 | -$21 | -$18 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | -$6 | -$13 | -$21 | -$18 |
| % Margin | – | -257.8% | -422.1% | -316.6% |
| EPS | -17.28 | -2.46 | -5.48 | -6.1 |
| % Growth | -602.4% | 55.1% | 10.2% | – |
| EPS Diluted | -17.28 | -2.46 | -5.48 | -6.1 |
| Weighted Avg Shares Out | 0 | 5 | 4 | 3 |
| Weighted Avg Shares Out Dil | 0 | 5 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $2 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$11 | -$14 | -$22 |
| % Margin | – | -217.1% | -277.7% | -395.2% |